Evidence map›Paper›PMID 36916944›Full record

ArticleAntimicrobial agents and chemotherapy2023

Efavirenz-Based Antiretroviral Therapy but Not Pregnancy Increased Unbound Piperaquine Exposure in Women during Malaria Chemoprevention.

Howard Hong, Usman Aslam-Mir, Richard Kajubi, Erika Wallender, Norah Mwebaza, Grant Dorsey, Philip J Rosenthal, Francesca T Aweeka, Liusheng Huang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Howard HongDrug Research Unit, Department of Clinical Pharmacy, University of California, San Francisco, California, USA.ORCID 0000-0001-8586-5764
Usman Aslam-MirDrug Research Unit, Department of Clinical Pharmacy, University of California, San Francisco, California, USA.
Richard KajubiInfectious Disease Research Collaboration, Makerere University College of Health Sciences, Kampala, Uganda.
Erika WallenderDrug Research Unit, Department of Clinical Pharmacy, University of California, San Francisco, California, USA.ORCID 0000-0003-1166-1587
Norah MwebazaInfectious Disease Research Collaboration, Makerere University College of Health Sciences, Kampala, Uganda.
Grant DorseyDepartment of Medicine, University of California, San Francisco, California, USA.
Philip J RosenthalDepartment of Medicine, University of California, San Francisco, California, USA.ORCID 0000-0002-7953-7622
Francesca T AweekaDrug Research Unit, Department of Clinical Pharmacy, University of California, San Francisco, California, USA.
Liusheng HuangDrug Research Unit, Department of Clinical Pharmacy, University of California, San Francisco, California, USA.ORCID 0000-0003-2702-4486
University of California, San Francisco · USMakerere University · UG

Funding

Clinical and Translational Science InstituteUL1TR001872 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLARD, HAROLD R, JACOBY, VANESSA · 2016 to 2025
$112.1M
The immunologic consequences of prenatal exposure to malariaP01HD059454 · NICHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 2008 to 2017
$22.6M
Pharmacological insights into antimalarial exposure, clinical outcomes, and drug resistance in AfricaR01AI117001 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AWEEKA, FRANCESCA T., ROSENTHAL, PHILIP JON · 2015 to 2024
$7.1M
Unbound piperaquine pharmacokinetic exposure in Ugandan pregnant women and children receiving malaria chemopreventionR21AI153848 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HUANG, LIUSHENG · 2021 to 2022
$444k
NCATS NIH HHS UL1 TR001872NIAID NIH HHS R01 AI117001NIAID NIH HHS R21 AI153848NICHD NIH HHS P01 HD059454
6 · The paper itself

Abstract

Dihydroartemisinin-piperaquine (DP) is highly effective for malaria chemoprevention during pregnancy, but the standard dosing of DP that is used for nonpregnant adults may not be optimal for pregnant women. We previously reported that the pharmacokinetic exposure of total piperaquine (PQ; both bound and unbound to plasma proteins) is reduced significantly in the context of pregnancy or efavirenz (EFV)-based antiretroviral therapy (ART). However, as PQ is >99% protein-bound, reduced protein binding during pregnancy may lead to an increase in the pharmacologically active unbound drug fraction (f

Indexed as

AntimalarialsHIV InfectionsMalariaQuinolinesAdultAlkynesArtemisininsBenzoxazinesChemopreventionCyclopropanesFemaleHumansPiperazinesPregnancyAlkynesAntimalarialsArtemisininsartenimolBenzoxazinesCyclopropanesefavirenzpiperaquinePiperazinesQuinolinesdrug-drug interactionefavirenzmalariapregnancyultrafiltrationunbound piperaquine

Identifiers

PMID36916944
PMCPMC10112216
OpenAlexW4324129830

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.